Protara Therapeutics, Inc.
TARA
$3.40
-$0.12-3.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -10.33% | 39.21% | 39.27% | 33.89% | 38.71% |
| Total Depreciation and Amortization | -2.64% | 15.53% | 19.73% | 29.00% | 37.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -33.21% | -85.70% | -84.64% | -83.60% | -82.79% |
| Change in Net Operating Assets | 196.81% | 189.05% | 142.45% | 136.63% | -867.90% |
| Cash from Operations | 4.66% | -3.89% | -2.01% | -23.48% | -41.95% |
| Capital Expenditure | -40.00% | -23.53% | 5.15% | 66.09% | 62.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -63.84% | -44.64% | 42.48% | 174.55% | 252.70% |
| Cash from Investing | -63.93% | -44.81% | 42.62% | 175.70% | 255.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 8.79% | 8.79% | -34.15% | -25.61% | -1.11% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 153,797.80% | 46,271.43% | 51,306.10% | -25.61% | -1.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 697.02% | 231.02% | 34,012.27% | 808.84% | 233.30% |